UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________________ to _________________________________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its ch ...

Bio-Rad Laboratories, Inc (NYSE:BIO) Q4 2018, Earnings Conference Call February 28, 2019 5:00 PM ET Company Participants Ron Hutton – Vice President and Treasurer Christine Tsingos – Executive Vice President and Chief Financial Officer Norman Schwartz – Chief Executive Officer John Hertia – President of our Clinical Diagnostics Group Annette Tumolo – President of our Life Science Group Conference Call Participants Brandon Couillard – Jefferies LLC Patrick Donnelly – Goldman Sachs Dan Leonard – Deutsche Bank ...

Bio-Rad Laboratories, Inc. J.P. Morgan Healthcare Conference 2019 BIO RAD Forward-Looking Statements Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding our investment in high growth emerging markets and new products and technologies, our new focus on lab to clinic solutions, improvements to our operational efficiency and our future financial performance. Forward ...